Capecitabine pharmacogenetics: historical milestones and progress toward clinical implementation.
Department of Haematology-Oncology, National University Cancer Institute, Singapore 119228.|Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599.|Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600.
Nicholas
N
Syn
Department of Haematology-Oncology, National University Cancer Institute, Singapore 119228.|Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599.
Soo-Chin
SC
Lee
Department of Haematology-Oncology, National University Cancer Institute, Singapore 119228.|Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599.|Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600.
Boon-Cher
BC
Goh
Department of Haematology-Oncology, National University Cancer Institute, Singapore 119228.|Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599.
Wei-Peng
WP
Yong
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D000069287:Capecitabine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D010597:Pharmacogenetics / Q000379:methods*; D013940:Thymidylate Synthase / Q000235:genetics
D000069287:Capecitabine; D013940:Thymidylate Synthase
DPYD; TYMS; Xeloda; capecitabine; fluoropyrimidines; hand–foot syndrome; pharmacogenetics; ­thymidylate synthase